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Background: Some relationships are established between diabetes mellitus (DM) and a series 
of cutaneous disorders. Specific dermatoses are markers for undiagnosed DM. Other disorders 
represent supervening complications in an already treated DM patient.
Objective: To review the information about dermocosmetic care products and their appropriate 
use in the management and prevention of dermatoses related to DM.
Method: The peer-reviewed literature and empiric findings are covered. Owing to the limited 
clinical evidence available for the use of dermocosmetics, a review of the routine practices and 
common therapies in DM-related dermatoses was conducted.
Results: Some DM-related dermatoses (acanthosis nigricans, pigmented purpuric dermatosis) 
are markers of macrovascular complications. The same disorders and some others (xerosis, 
Dupuytren’s disease) have been found to be more frequently associated with  microangiopathy. 
Other skin diseases (alopecia areata, vitiligo) were found to be markers of autoimmunity, par-
ticularly in type 1 DM. Unsurprisingly, using dermocosmetics and appropriate skin care has 
shown objective improvements of some DM-related dermatoses, such effects improve the quality 
of life. The most common skin manifestations of DM fall along continuum between “dry skin,” 
xerosis, and acquired ichthyosis, occurring predominately on the shins and feet. Dermocosmetic 
products improve the feeling of well-being for DM patients.
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Introduction
Diabetes mellitus (DM) is a metabolic disorder corresponding to a relative-to- complete 
insulin deficiency. This condition leads to gross alterations in glucose, fat, and protein 
metabolism. In type 1 DM, insulin insufficiency results from a gradual, immune-
mediated destruction of the pancreatic β islet cells. By contrast, in type 2 DM, chronic 
hyperglycemia mainly results from end-organ (particularly the liver and skeletal 
muscles) insulin resistance. This condition is accompanied by a progressive, age-
related decrease in pancreatic insulin release. A genetic predisposition and a strong 
association with obesity exist in type 2 DM.
DM is a major cause of morbidity and mortality. Any skin structure may be altered 
by DM. The prevalence of DM-associated skin morbidity is far from being trivial.1–7 
Some disorders represent an early indicator of a yet undiagnosed DM. Other skin 
changes occur even when adequate DM treatment has already been initiated. Two 
types of noninfectious dermatoses with distinct pathobiologic background have been 
distinguished. These include some lesions, which are markers of poor glycemic control, 
and a cluster of skin changes representing DM-related manifestations of autoimmunity.8 
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The prevalence of DM-associated skin infections is  commonly 
increased compared with the normal population.7
One of the main direct biologic effects of hyperglycemia 
is nonenzymatic glycation, which alters various structural 
and regulatory proteins. This process occurs naturally during 
aging and is severely boosted in DM, leading to the build 
up of advanced glycation end (AGE) products. The amount 
of skin AGE products strongly correlates with DM-related 
microvasculopathy, including retinopathy and nephropa-
thy.9–14 Several immunomodulatory mechanisms are altered in 
DM and thus reduce the defense mechanisms to infections.
Of note, most of the DM-associated dermatoses are not 
specific for this endocrinopathy. Other pathogenic factors 
are possibly involved. Many of them have not been clearly 
identified so far.
During the last years, efforts have been streamed within 
the dermocosmetics and pharmaceutics industries towards 
the development of various topical treatments targeting some 
of the skin complications of DM. These have been mainly 
driven by the knowledge that at certain points of the disease, 
the existing therapies were no longer able to slow down the 
progression of the skin changes. Evidence-based support for 
the use of dermocosmetics as adjunctive therapy remains 
modest. Therefore, practice is based on anecdotal reports or 
studies with limited control.
This work provides an updated review of (a) the physio-
pathologic changes altering the skin of DM patients, and (b) 
the dermocosmetic formulations adapted to these conditions. 
Evidence-based support for the use of dermocosmetic formu-
lations and make-up as adjunctive DM management remains 
scarce. Practice is based on personal experience, anecdotal 
reports, and studies with limited control.
Direct skin complications of DM
The complications of DM directly affecting the skin involve 
the microvasculature, the extravascular dermal matrix, the 
dermoepidermal junction, the epidermis, hair follicles, 
sweat glands, and the hypodermis as well (Tables 1 and 2). 
Pruritus and sensorial irritation (sensitive skin) are frequently 
reported.6 Whenever possible, proactive management, using 
 dermocosmetic formulations, may prove to be critical for the 
perception of well-being in DM patients. Early education and 
continued encouragement most probably benefit patient qual-
ity of life. Skin cleansing removes dirt and other xenobiotics 
along with sebum. This can be harsh and may be particularly 
detrimental to skin when the skin barrier is already disturbed. 
Without professional guidance, patients may experiment 
with  inappropriate self-care behaviors. In general, due to the 
lack of evidence supporting their use, patients should avoid 
washing with aggressive soaps.
Angiopathy
Macro- and microangiopathy largely contribute to the 
 cutaneous complications of DM. DM patients have increased 
vascular leakiness, with increased vessel wall permeability. The 
vascular responsiveness to sympathetic innervation is lowered, 
as well as the response to thermal and hypoxemic stress.
Microangiopathy is a major complication of DM, as it 
is responsible for retinopathy, nephropathy, and peripheral 
neuropathy. The microvascular network of the skin is particu-
larly altered in DM, and this worsens with age.15 The perivas-
cular basement membranes are thickened, and the endothelial 
cells pile up.16,17 Type IV collagen and laminin are deposited 
in excess. The vascular lumen shows uneven dilation and 
narrowing. These latter changes are clinically obvious during 
periungual capillaroscopy. Similar aspects are found in facial 
rubeosis, diabetic dermopathy and necrobiosis lipoidica.
On the lower limbs, macroangiopathy of the large blood 
vessels is due to the combination of atherosclerosis and 
vasculitis. This condition is seen frequently in DM patients, 
in whom this is superimposed over microangiopathy. These 
combined processes lead to a chronic reduction in oxygen 
supply and is responsible for skin atrophy, foot hypothermia, 
vellus hair rarefaction, and onychodystrophies. In addition, 
distal neuropathy, as well as traumatisms and infectious 
agents, participates in the development of both DM ulcers 
and DM foot syndrome; once ulcer develops, peripheral vas-
cular disease and the intrinsic disturbance in wound healing 
contribute to adverse outcomes.18
No direct effect on micro- and macroangiopathy is 
expected from the use of dermocosmetic products.6 However, 
some formulations help to correct the consequences of the 
vascular damage. This is particularly the case for the products 
targeting dry/harsh skin by boosting epidermal renewal.6
Erythrosis
An erythrosis reaction is commonly present on the face of 
DM patients.8 Other parts of the body are possibly affected by 
Table 1 Skin disorders associated with DM
Type 1 DM Type 2 DM
Alopecia areata Acanthosis nigricans
Necrobiosis lipoidica Facial erythrosis
vitiligo Pigmented purpuric dermatosis 
Xerosis
Abbreviation: DM, diabetes mellitus.
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the same process as well. Daily photoprotection is important 
when the skin has become more sensitive to UV radiation 
and where treatments have lead to pigmentary changes. 
Recommendations point to the use of a broad-spectrum 
sunscreen with SPF and UVA-PF, depending on the patient’s 
phototype and photosensitivity.19,20 In addition, the use of 
appropriate nonirritant hygiene products are empirically 
recommended, in order to avoid a worsening of the clinical 
signs.
AGE products
The AGE products are implicated in the functional microan-
giopathy, secondary to the increased blood cell viscosity and 
the consecutive reduction in blood flow. The peripheral neu-
ropathy adds its functional effects to the glycation process, 
and the combination increases their clinical signs.21 In addi-
tion, glycation alters some physicochemical characteristics 
of the fibrous collagen, and glycation is further responsible 
for a yellowish hue of the skin and nails.
Skin glycation creates new molecular residues and 
induces cross-links in the extracellular matrix of the dermis. 
The formation of such cross-links between macromolecules 
contributes to altered elasticity and the modification of other 
physical characteristics of the dermis in DM patients, similar to 
those observed during intrinsic aging and photoaging.22 Some 
glycation inhibitors have been described.23,24 Aminoguanidine 
is probably the most widely used glycation inhibitor. Other 
compounds, including resveratrol, carnosine, and blueberry 
extract, exhibit some in vitro antiglycation activity. 
Nevertheless, studies evaluating the impact of topical products 
containing AGE inhibitor on the improvement of DM skin 
are currently missing. A 12-week study of 20 DM patients 
using a topical product enriched with an AGE inhibitor and 
a glycosaminoglycan (GAG) synthesis stimulator failed to 
show any change in skin AGE products, as evaluated by a 
skin autofluorescence measurement.25
Protein glycation is accompanied by the generation of 
reactive oxygen species (ROS) through the autoxidation 
of glucose and glycated proteins and via the interaction 
of AGE products with cell surface receptors for AGE 
(RAGE).11,14 Hence, the application of a topical product 
containing  antioxidants or a combination of antiglycation 
and  antioxidant has been postulated to be a safe and simple 
care targeting some DM skin complications.25
AGE products are clearly involved in some skin dis-
orders related to DM. However, the cross-links between 
macromolecules and the extracellular matrix, and the genera-
tion of ROS, are insufficient to explain the pathogenesis of 
all the DM-associated skin diseases.
Diabetic dermopathy
Diabetic dermopathy is a common nonspecific condition 
affecting as many as 30%–60% of DM patients. Lesions 
begin as multiple discretely erythematous, coin-shaped mac-
ules or annular rings and are prevalent on the shins. The skin 
spots commonly regress after a few years, leaving atrophic 
hyperpigmented areas. The vessel walls are thickened, and 
Factor XIIIa+ dermal dendrocytes are abundant. The occur-
rence of lesions correlate with retinopathy, nephropathy, 
and neuropathy.26 No treatment is necessary for individual 
atrophic macules; these are asymptomatic and are not directly 
associated with increased local morbidity.
Pigmented purpuric dermatosis
Pigmented purpuric dermatosis, also known under its 
eponym Schamberg disease, is prevalent in DM patients. It 
is characterized by a discrete, lymphoid capillaritis, showing 
leakage of erythrocytes. A drug reaction is identified in some 
patients. This condition is closely related to alterations of the 
perivascular basement membranes.17
We suggest that the presence of yellow skin on the hands, 
rubeosis faciei, and pigmented purpuric dermatosis can 
prompt the use of make-up with a high pigment concentration, 
to cover the skin lesions. It is important to avoid any occlusive 
effect at risk of worsening the clinical manifestations.
Necrobiosis lipoidica
Necrobiosis lipoidica is a rare disorder affecting about 
0.3% of DM patients. This skin condition predominantly 
affects women, from 30–40 years and older. It is considered 
Table 2 Correlations reported between some dermatoses and DM complications
Dermatosis Macroangiopathy Nephropathy Retinopathy Neuropathy
Acanthosis nigricans81 + +
Dermopathy26 + + +
Dupuytren’s disease32 +
Pigmented purpuric dermatosis17 + +
Sclerodermoid syndrome29 + +
Abbreviation: DM, diabetes mellitus.
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as a skin marker of possible DM. However, the severity of 
hyperglycemia and poor diabetic control do not correlate 
with the occurrence of necrobiosis lipoidica. Skin lesions 
appear as infiltrated yellow-brown plaques, often located 
on the shins. The macules merge to form sharply circum-
scribed scleroatrophic plaques with scalloped outlines. 
The clinical course is often indolent, with spontaneous 
remission in less than 20% of cases. By contrast, painful 
ulcerations can develop, and wound healing is particularly 
difficult. A lymphoid cell infiltrate is distributed through-
out the dermis with focal collections, in a granulomatous 
pattern. A prominent microangiopathy is present, and the 
perivascular stroma is remodeled with abundant deposits 
of acidic proteoglycans, collagen bundles, and lipids. 
Dermal dendrocytes are quite numerous in the early lesions. 
They are likely involved in the active process of dermal 
remodelling.27
At present, the treatment of necrobiosis lipoidica is 
disappointing. A focus should be placed on the prevention 
of ulcers.
Granuloma annulare
Granuloma annulare histopathologically resembles focal 
areas of necrobiosis lipoidica somewhat. In rare instances, 
it is associated with DM, particularly when the pattern of 
distribution is widespread. The association of necrobiosis 
lipoidica with granuloma annulare and sarcoidosis has been 
reported.28
Thick and waxy diabetic skin
Several specific scleroderma-like syndromes are associated 
with a localized thickening of the skin, in DM.29 The com-
mon underlying pathogenesis involves molecular alterations 
in collagen and GAGs. The clinical syndromes are the result 
of increased deposition and improper degradation of these 
macromolecules, and they are likely related to the formation 
of AGE products.
About 30% of patients with type 1 and type 2 DM exhibit 
a waxy infiltration of the skin of the extremities, generally 
associated with painless, limited joint mobility. This presen-
tation is a marker of microangiopathy risk, but it remains 
unclear whether the pathogenic origins of the skin and joints 
are similar. The viscoelastic properties of the skin are usually 
more altered in type 1 DM than in type 2 DM. Monitoring 
these changes could help predicting the evolution of DM.30,31 
Acral pseudoscleroderma is a risk indicator for nephropathy 
in type 1 DM. It is also predictive for retinopathy and neu-
ropathy in both DM types.
Most important, intensive insulin therapy is central in 
the prevention and, possibly, the treatment of limited joint 
mobility and scleroderma-like syndrome. Long-term tight 
glycemic control leads to decreased AGE products in the skin, 
and delayed onset and severity of limited joint mobility.32
Scleredema diabeticorum
Scleredema affects about 30% of type 2 DM patients, 
particularly obese men.33 The skin is typically infiltrated 
and indurated on the upper back, neck, shoulders, and 
occasionally the chest. The dermis is thickened, and the 
collagen bundles are coarse and embedded in an excess of 
acidic GAGs. The glycation process is probably involved 
in the pathogenesis of scleredema. Most patients with 
DM-scleredema become insulin dependent. Scleredema 
is difficult to treat,34–36 and these patients have multiple 
complications of DM.37
Perforating disorders
In severe DM patients prone to renal failure, perforating 
collagenosis is occasionally present on the extensor aspects 
of the extremities. Hyperkeratotic papules contain collagen 
fibres in their way of transepidermal extrusion. These lesions 
are pruriginous, and an isomorphic phenomenon is com-
monly present. Treatment for the perforating disorders is 
usually unsuccessful.36 Again, the focus should be placed 
on prevention, by avoiding excessive friction and pressure 
forces.
Diabetic bullosis
Abrupt spontaneous blisters occasionally develop on 
the lower extremities of type 1 DM patients suffering 
from peripheral neuropathy. The epidermis is lifted off 
at the level of the dermoepidermal basement membrane. 
Immunoreactants (immunoglobulins, complement) are 
typically absent in the skin lesions. The pathogenesis 
remains uncertain, although the neuropathy seems to play 
a prominent role.38
Diabetic bullosis is, in part, prevented by frequent topi-
cal applications of dermocosmetic formulations, increasing 
the epidermal biologic activity and reducing the mechanical 
impact of xerosis.
Diabetic xerosis and callus
Xerosis is a common feature in DM patients.7,39 It results 
from an abnormal, persistent cohesion between corneocytes, 
with secondary thickening of the tidy stratum corneum 
(SC), impaired moisturization of the uppermost SC layers, 
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increased transit time of corneocytes in the SC, and altered 
skin barrier function.39–43 Diabetic xerosis appears to be 
 correlated with microangiopathy.
Clinical evaluations of xerosis44 are conveniently mag-
nified, using dedicated noninvasive biometrological meth-
ods.45–47 These have shown the effects of aging and those of 
the environment to be superimposed over the consequences of 
DM.48–50 The physical characteristic of the SC depends on its 
water-content and -holding capacity.51,52 Electrometric mea-
surements represent a convenient method for monitoring SC 
moisture.53–58 Harvesting the superficial corneocytes can also 
provide information about the severity of xerosis.59–65 Finally, 
the rate of exfoliation is conveniently assessed using the dan-
syl chloride test 66–68 or the dihydroxyacetone test.69,70
Callus formation results from excessive pressure. It 
precedes necrosis and the breakdown of the soft tissue over 
the bony prominences of the feet, usually on the big toe and 
sole, and over the first and/or second metacarpophalangeal 
joints.71 Foot DM ulcers are surrounded by a ring of callus. 
Xerosis and callus prevention are important interventions 
that physicians and other health care professionals should 
provide to decrease the risk of DM ulcer.
Moisturizers and emollients bind water to the SC, 
improving the skin surface hydration. This has been repeat-
edly shown to improve the epidermal barrier function and to 
reduce the stinging, scaling, redness, and cracks associated 
with xerosis.72–78 Adequate hydration improves the barrier 
function, reduces pruritus, and prevents infections related 
to scratching.74
Although emollients represent a regular adjunct to other 
topical treatments for patients affected by some dermatoses, 
studies evaluating their impact on skin improvement in DM 
are few in number. Xerosis and reduced SC elasticity pos-
sibly lead to SC cracks, followed by bacterial invasion and 
infection. Recently, it was shown that an increased severity 
in xerosis was linked to the duration of DM. This condition 
was associated with desquamation and pruritus. Emollients 
frequently counteract all these alterations.79
Urea-based formulations enhance the penetration of 
other topical agents applied to thickened, keratotic, scaly 
skin.79 The prevention and removal of callus, especially in 
high-risk patients, plays a crucial role in ulcer prevention by 
significantly reducing focal plantar pressures. High concen-
tration urea-based moisturizers may be particularly suitable 
for the removal and prevention of hyperkeratosis and callus 
(Figure 1). In addition, the proper applications of topical 
agents by the patient reduces costs associated with podiatric 
treatments and possibly improves compliance to skin care.79
Acanthosis nigricans
Some patients with type 2 DM are prone to develop 
 acanthosis nigricans. The lesions present clinically as a brown 
to gray-black, velvety, and papillomatous thickening of the 
skin. The lesions typically involve large folds, particularly the 
axillae, the posterolateral neck, groins, and abdominal folds. 
Any other part of the body can also be involved, including 
the palms (tripe palms) and soles. Associated skin tags are 
common.
Acanthosis nigricans is a marker for a group of endo-
crine disorders characterized by insulin resistance, which 
can be present in type 2 DM.80,81 The action of insulin on 
the insulin-like growth factor-1 (IGF-1)-receptor appears to 
mediate abnormal epidermal proliferation and the resulting 
presentation of acanthosis nigricans. Any occurrence of DM-
related acanthosis nigricans represents a prognostic indicator 
for micro- and macrovascular complications. The treatment 
of acanthosis nigricans is generally ineffective. Topical treat-
ment with calcipotriol, salicylic acid, urea, systemic and topi-
cal retinoids have all been used with anecdotal success.82
Onychodystrophy
Onychodystrophies are frequent in DM patients, although 
none are specific for DM.83 They include Beau’s lines, 
onycholysis, yellowish discoloration, and splinter blood 
suffusions. The lesions are possibly more severe in winter, 
reflecting functional changes associated with the micro- and 
macroangiopathy.83
Compared to non-DM subjects with nail alterations, DM 
patients show a higher proportion of onychomycosis relative 
to noninfectious onychodystrophies.84 DM men suffer more 
frequently from onychomycosis and onychodystrophy than 
DM women. DM patients with compromised lower extremi-
ties and severe neuropathy are at increased risk for develop-
ing complications from onychomycosis. Thus, there is an 
A B
Figure 1 Profilometry of the skin surface in a diabetic patient. The sample comprises 
an untreated xerotic part (A) and a contiguous field (B) treated for 5 days with a 
urea-based cosmetic formulation. 
Note: The amplitude of the skin surface relief is reduced by half on the treated area.
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important clinical rationale for early identification and for 
adequately treating DM patients with nail alterations.
Reduced hair fullness
Hair is thinned, fragile and sparse on the scalp of DM 
patients.85 Corporal vellus hairs are possibly affected 
as well.
Altered sweating
Sweating is reduced on the lower extremities of DM patients. 
This condition results from the peripheral neuropathy. There 
is some compensatory hyperhidrosis on the upper part of 
the body.86–95 In areas with excessive sweating, a gentle 
antiperspirant or deodorant dedicated to these patients may 
be of interest.94
Pruritus
Pruritus is frequently present in DM patients.96 Occasionally, 
this predominates on the genital areas.
Membranous lipodystrophy
Membranous lipodystrophy refers to pseudocystic cavities 
located in the hypodermis following the focal necrosis of 
lobules of adipose cells. A hyaline shell is commonly present 
at the periphery of the lesions.




It is not clearly established that patients with poor glycemic 
control are more susceptible to common bacterial skin infec-
tions than the normal population. However, the response 
to infection is commonly weakened. It is important that 
DM patients maintain an intact mucocutaneous barrier. 
Dermatophytoses are not more prevalent in DM but open the 
way to other common pathogens. In such instance, erysipela 
frequently ensues.
Mucocutaneous infections with Candida spp. are an 
early indicator of an undiagnosed DM or an inadequately 
controlled glycemia. They exhibit various clinical presen-
tations. The adhesion of Candida yeasts to the SC is pos-
sibly increased in DM patients compared with the normal 
population.97
It is important to pay attention to rare but severe skin 
infections, including the malignant external otitis due to 
Pseudomonas aeruginosa and the necrotizing soft tissue 
infections. Hyperglycemia favors some other  opportunistic 
diseases, such as the devastating infections caused by 
 Mucorales zygomycetes. Facial rhinocerebral mucormycosis 
is a typical example.
Secondary metabolic changes
Xanthochromia responsible for a yellowish hue is in part 
linked to the xerotic process. Carotenemia is occasion-
ally present in DM patients and confers an orange hue to 
the skin.
Eruptive xanthomas can onset rapidly as a result of 
major hypertriglyceridemia, in poorly controlled DM. They 
occur as crops of yellowish tiny papules surrounded by an 
erythematous halo, grouped on the extensor aspects the 
limbs. The lesions are due to a lipidic load in the perivascular 
dendrocytes.98
Associated diseases
The increased prevalence of type 1 DM is associated with 
a series of immune-mediated disorders, including vitiligo, 
alopecia areata, dermatitis herpetiformis, autoimmune thy-
roiditis, and Biermer’s anemia.99 Generalized eruptive clear 
cell syringomas are particularly associated with DM.
Migratory necrolytic erythema is a rare disorder in the 
glucagonoma syndrome spectrum. This latter neoplasm is 
issued from the alpha cells in the Langerhans islets of the 
pancreas.
Complications of DM treatments
Drug reactions rarely occur following oral DM therapy. 
However, a maculopapular rash may develop during the 
first months of treatment. Urticaria, lichenoid eruptions, 
Stevens-Johnson syndrome, and toxic epidermal necrolysis 
have all been reported.100 Adverse reactions to insulin are 
rare.101 Nevertheless, lipohypertrophic lesions, mainly in the 
abdominal wall, are still quite commonly observed in patients 
chronically treated with a continuous subcutaneous insulin 
infusion, even with ultrashort insulin analogs.102
Conclusion
Metabolic changes associated with DM exert a major impact 
on the skin. The microvascular network is particularly altered. 
The nonenzymatic glycation of diverse macromolecules 
is a major biologic factor, as is the peripheral neuropathy. 
Cutaneous disorders associated with DM commonly bother 
and cause pain to DM patients, and impact their quality of 
life, including interpersonal relationships. Cosmetics and 
appropriate skin care management contribute to a feeling 
of well-being and comfort.79 Unsurprisingly, they have been 
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shown to objectively improve the quality of life of DM 
patients.50 Clearly, skin care with moisturizers, low-irritant 
cleansers, and make-up may be effective in improving skin 
physiology and controlling or covering up some dermatoses 
associated with DM.
Some recommendations are expressed:
•	 There is evidence suggesting that daily applications of 
a moisturizing formulation on the body, particularly 
on compromised lower extremities, often control both 
pruritus and xerosis. Emollients containing urea, with 
or without antiglycation agents and antioxidants, may 
be indicated.
•	 The prevention and removal of callus remain essential.
•	 Products containing phthalate should be discarded, 
although further studies are needed to determine whether 
phthalate exposure alters glucose metabolism and 
increases the risk of insulin resistance and DM.103
•	 Applications of a broad-spectrum sunscreen to the face 
and other sun-exposed areas (ie, neck and arms) should 
limit any enhancement of skin glycation related to sun 
exposure.
•	 The covering of pigmented lesions is likely to improve 
well-being.
These recommendations are intended to prevent and/or 
optimize the therapeutic management of DM-associated 
dermatoses, which become more prevalent with aging.104 
Hence, they will improve the quality of life of DM patients, 
allowing them to better enjoy their lives.
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